Josh, I would go this way. First, we don't think it's all about price. If you're in the -- if you go back to our quadrant, if you're in the upper end of the -- upper side to those, it's clearly more price-sensitive, because those customers are sort of like, "Just give me a name I recognize." So they tend to be a little more price-sensitive. We've tried to design our value propositions to recognize price is important, but that value is equally important. We don't get as much leakage between independent agencies, pricing and the captive channel. When you look at where our business comes from or where it goes, there's not -- obviously, people who want local advice go to the same kind of person, but we don't see a huge amount of pressure. If somebody in the independent agency channel takes that price down, we don't see a big change there. The -- as it relates to overall pricing, I would say we're sort of in line this year with our -- if you look at the top 3 competitors, top 7 states, we look in line with those people; not a big difference. Progressive might be at the low end. GEICO and State Farm would be slightly higher. But in the range of -- hard for a customer to tell. If you're talking about 0.5 points, $1,000 a year, $900 a year, you're talking about $5, so it doesn't really matter from a price elasticity standpoint. As it relates to what other people do in the future, I think Matt described how we run our business. We do the same thing in Esurance and Encompass, which is highly specific, we watch our cost, look at our value proposition, make sure it's fair to our customers. So I wouldn't -- and as it relates to Travelers taking big decrease, I think theirs was also related to a different product, and Don Bailey is shaking, may have some comment. But I think you're starting to see more people move to product differentiations. So if you look over a longer period of time, competition first was on sophisticated pricing, then it moved to advertising, particularly in the branded channels. And now it's moving to product differentiation.
Josh Stirling - Sanford C. Bernstein & Co., LLC., Research Division: That's helpful, that's helpful. And if I can just ask just one more quick question. Severity last year, everybody was generally concerned about it. It led to a bunch of price increases. Your guys' metrics, I mean, are still going up, of course, but seem to be moderating a bit. And there was some commentary coming from other companies that sort of suggested maybe the severity spike that everybody feared hasn't materialized. And I'm wondering if you guys have any color around that, or whether maybe people are just reacting to noise?